NASDAQ:EFTR eFFECTOR Therapeutics (EFTR) Stock Price, News & Analysis → The system that called 2023’s top 7 stocks is at it again… (From WealthPress) (Ad) Free EFTR Stock Alerts $1.95 +0.06 (+3.02%) (As of 10:33 AM ET) Add Compare Share Share Today's Range$1.92▼$2.0050-Day Range$1.70▼$16.9552-Week Range$1.60▼$37.00Volume27,800 shsAverage Volume321,149 shsMarket Capitalization$7.18 millionP/E RatioN/ADividend YieldN/APrice Target$24.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get eFFECTOR Therapeutics alerts: Email Address eFFECTOR Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside1,132.7% Upside$24.00 Price TargetShort InterestHealthy7.16% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.50Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($5.18) to ($2.03) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.68 out of 5 stars 3.5 Analyst's Opinion Consensus RatingeFFECTOR Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageeFFECTOR Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted7.16% of the float of eFFECTOR Therapeutics has been sold short.Short Interest Ratio / Days to CovereFFECTOR Therapeutics has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in eFFECTOR Therapeutics has recently decreased by 29.32%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldeFFECTOR Therapeutics does not currently pay a dividend.Dividend GrowtheFFECTOR Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for EFTR. Previous Next 3.1 News and Social Media Coverage News SentimenteFFECTOR Therapeutics has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.34 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for eFFECTOR Therapeutics this week, compared to 1 article on an average week.Search Interest15 people have searched for EFTR on MarketBeat in the last 30 days. This is an increase of 36% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added eFFECTOR Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, eFFECTOR Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.40% of the stock of eFFECTOR Therapeutics is held by insiders.Percentage Held by Institutions57.67% of the stock of eFFECTOR Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for eFFECTOR Therapeutics are expected to grow in the coming year, from ($5.18) to ($2.03) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of eFFECTOR Therapeutics is -0.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of eFFECTOR Therapeutics is -0.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad WealthPressIt’s now possible to know the win rate of every trade… BEFORE you take it! Would you like to know the historic win rate of every trade you take before you place it? Well, it’s all possible with these FIVE Candlestick Pattern Cheatsheets. >> You can grab your FREE, laminated copies right here << About eFFECTOR Therapeutics Stock (NASDAQ:EFTR)eFFECTOR Therapeutics, Inc., a biopharmaceutical company, engages in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer. The company's lead product candidates comprise Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer; and Zotatifin, a small molecule inhibitor of eukaryotic initiation factor 4A (eIF4E), which is in Phase 1/2 clinical trial to treat patients with solid tumors, as well as completed Phase 2a open-label expansion cohort in combination with fulvestrant and abemaciclib to treat patients with ER+ breast cancer. The company has a research collaboration and license agreement with Pfizer Inc. to research and develop small molecules that target eIF4E. eFFECTOR Therapeutics, Inc. was incorporated in 2012 and is headquartered in Solana Beach, California.Read More EFTR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart EFTR Stock News HeadlinesApril 23, 2024 | americanbankingnews.comAnalyzing COMPASS Pathways (NASDAQ:CMPS) and eFFECTOR Therapeutics (NASDAQ:EFTR)April 9, 2024 | globenewswire.comeFFECTOR Therapeutics to Participate in Upcoming Investor ConferenceApril 29, 2024 | Banyan Hill Publishing (Ad)The Best AI Stock to Own in the World Today is Trading for Just $25“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.April 4, 2024 | marketwatch.comEFFECTOR Therapeutics Shares Drop as Development of Lung Cancer Treatment Drug EndsApril 4, 2024 | markets.businessinsider.comEFFECTOR Reports Results Of Phase2 KICKSTART Trial Of Tomivosertib-Pembrolizumab In NSCLCApril 4, 2024 | finance.yahoo.comCancer-Focused eFFECTOR Therapeutics Shelves Development Of Lung Cancer Candidate After Disappointing DataApril 4, 2024 | globenewswire.comeFFECTOR Therapeutics Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined with Pembrolizumab in Non-Small Cell Lung CancerMarch 28, 2024 | markets.businessinsider.comBuy Rating for eFFECTOR Therapeutics Backed by Solid Financials and Promising Zotatifin TrialsApril 29, 2024 | Banyan Hill Publishing (Ad)Forget AI, Imperium Is Expected to Grow 320,00% in 3 YearsIf you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)March 27, 2024 | finanznachrichten.deeFFECTOR Therapeutics, Inc.: eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateMarch 25, 2024 | investorplace.comEFTR Stock Earnings: eFFECTOR Therapeutics Misses EPS for Q4 2023March 25, 2024 | globenewswire.comeFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateMarch 19, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: eFFECTOR Therapeutics (EFTR), Apellis Pharmaceuticals (APLS) and Ultragenyx Pharmaceutical (RARE)February 6, 2024 | markets.businessinsider.comBuy Rating Affirmed for eFFECTOR Therapeutics Amid Promising Oncology Drug Milestones and Extended Financial RunwayJanuary 31, 2024 | msn.comeFFECTOR Therapeutics Regains Nasdaq Compliance StatusJanuary 30, 2024 | finance.yahoo.comDoes eFFECTOR Therapeutics, Inc. (EFTR) Have the Potential to Rally 814.53% as Wall Street Analysts Expect?January 25, 2024 | finance.yahoo.comeFFECTOR Therapeutics Announces $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesJanuary 10, 2024 | finanznachrichten.deeFFECTOR Therapeutics, Inc.: eFFECTOR Therapeutics Announces Reverse Stock SplitJanuary 9, 2024 | msn.comeFFECTOR Therapeutics announces 1-for-25 reverse stock splitDecember 8, 2023 | msn.comeFFECTOR Therapeutics Discloses Updated Data From Mid-Stage Breast Cancer StudyDecember 8, 2023 | finance.yahoo.comeFFECTOR Therapeutics Announces New Positive Interim Data from Dose Escalation and Phase 2 Expansion Cohorts of Zotatifin in ER+ Metastatic Breast Cancer PatientsNovember 28, 2023 | msn.comeFFECTOR stock rises after FDA fast track status for breast cancer therapyNovember 17, 2023 | markets.businessinsider.comBuy Rating for eFFECTOR Therapeutics Based on Promising Drug Developments and Capital SecurityNovember 13, 2023 | msn.comeFFECTOR Therapeutics GAAP EPS of -$0.13 misses by $0.01November 13, 2023 | tmcnet.comeFFECTOR Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateSeptember 20, 2023 | fool.comeFFECTOR Therapeutics (NASDAQ: EFTR)August 25, 2023 | msn.comHC Wainwright starts eFFECTOR at buy, cites drug technology platformSee More Headlines Receive EFTR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for eFFECTOR Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/25/2024Today4/28/2024Next Earnings (Estimated)5/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:EFTR CUSIPN/A CIK1828522 Webwww.locustwalkacquisitioncorp.com Phone858-925-8215FaxN/AEmployees14Year FoundedN/APrice Target and Rating Average Stock Price Target$24.00 High Stock Price Target$24.00 Low Stock Price Target$24.00 Potential Upside/Downside+1,169.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($16.92) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-35,810,000.00 Net MarginsN/A Pretax Margin-5,332.49% Return on EquityN/A Return on Assets-160.00% Debt Debt-to-Equity RatioN/A Current Ratio0.77 Quick Ratio0.77 Sales & Book Value Annual Sales$3.55 million Price / Sales1.96 Cash FlowN/A Price / Cash FlowN/A Book Value($1.94) per share Price / Book-0.97Miscellaneous Outstanding Shares3,690,000Free Float3,377,000Market Cap$6.97 million OptionableOptionable Beta0.52 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesDr. Stephen T. Worland Ph.D. (Age 66)CEO, President & Director Comp: $873.96kMr. Michael Byrnes M.B.A. (Age 47)Chief Financial Officer Comp: $654.82kDr. Douglas Warner M.D. (Age 52)Chief Medical Officer Comp: $660.16kDr. Davide Ruggero Ph.D.Co-Founder and Member of Clinical & Scientific Advisory BoardDr. Kevan M. Shokat Ph.D.Co-Founder and Member of Clinical & Scientific Advisory BoardKey CompetitorsCan-Fite BioPharmaNYSE:CANFTrevenaNASDAQ:TRVNGraybug VisionNASDAQ:GRAYClever LeavesNASDAQ:CLVRKinetaNASDAQ:KAView All CompetitorsInsidersSr One Capital Management, LlcSold 24,366 sharesTotal: $371,581.50 ($15.25/share)View All Insider Transactions EFTR Stock Analysis - Frequently Asked Questions Should I buy or sell eFFECTOR Therapeutics stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for eFFECTOR Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" EFTR shares. View EFTR analyst ratings or view top-rated stocks. What is eFFECTOR Therapeutics' stock price target for 2024? 2 analysts have issued 1 year price targets for eFFECTOR Therapeutics' shares. Their EFTR share price targets range from $24.00 to $24.00. On average, they anticipate the company's stock price to reach $24.00 in the next year. This suggests a possible upside of 1,132.7% from the stock's current price. View analysts price targets for EFTR or view top-rated stocks among Wall Street analysts. How have EFTR shares performed in 2024? eFFECTOR Therapeutics' stock was trading at $11.6850 on January 1st, 2024. Since then, EFTR shares have decreased by 83.3% and is now trading at $1.9470. View the best growth stocks for 2024 here. Are investors shorting eFFECTOR Therapeutics? eFFECTOR Therapeutics saw a decrease in short interest in the month of April. As of April 15th, there was short interest totaling 244,000 shares, a decrease of 29.3% from the March 31st total of 345,200 shares. Based on an average trading volume of 372,800 shares, the short-interest ratio is presently 0.7 days. Currently, 7.2% of the shares of the stock are short sold. View eFFECTOR Therapeutics' Short Interest. When is eFFECTOR Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our EFTR earnings forecast. How were eFFECTOR Therapeutics' earnings last quarter? eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR) announced its quarterly earnings results on Monday, March, 25th. The company reported ($3.42) earnings per share for the quarter, missing analysts' consensus estimates of ($2.73) by $0.69. When did eFFECTOR Therapeutics' stock split? eFFECTOR Therapeutics's stock reverse split on Friday, January 12th 2024. The 1-25 reverse split was announced on Friday, January 12th 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, January 12th 2024. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. How do I buy shares of eFFECTOR Therapeutics? Shares of EFTR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:EFTR) was last updated on 4/29/2024 by MarketBeat.com Staff From Our PartnersAI finds its first serious applicationWall Street StarHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportHe Is Giving Away BitcoinCrypto Swap ProfitsThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyBiden out June 13; Kamala won’t replace him?Paradigm PressGreat Crypto BullWeiss RatingsWhy Big Pharma is Investing Billions in This BiotechBehind the Markets4 Cryptos BETTER than BitcoinTrue Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding eFFECTOR Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
